Sort by:
Need a comprehensive medical report on "Boehringer Ingelheim"?
Analyze the latest clinical research and treatment options
Summarize scientific findings from medical journals
Post Marketing Surveillance of Alesion® in Japanese Paediatric Patients With Allergic Rhinitis, Eczema/Dermatitis, Urticaria and Pruritus
Completed
- Conditions
- Rhinitis, Allergic, Perennial
- Interventions
- Drug: Alesion®
- First Posted Date
- 2014-09-12
- Last Posted Date
- 2014-09-12
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 3793
- Registration Number
- NCT02238236
Safety Trial of Atrovent® in Pediatric Patients With Rhinorrhea Associated With a Common Cold or Allergy
- First Posted Date
- 2014-09-12
- Last Posted Date
- 2014-09-12
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 230
- Registration Number
- NCT02238210
Observational Study in Parkinson's Disease of the Primary Care Population of Patients Treated With Pramipexole
- First Posted Date
- 2014-09-11
- Last Posted Date
- 2014-09-11
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 497
- Registration Number
- NCT02236728
The Use of Pramipexole and Other Dopamine Agonists and the Risks of Heart Failure and Pneumonia
- First Posted Date
- 2014-09-11
- Last Posted Date
- 2014-09-11
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 26814
- Registration Number
- NCT02236741
Postmarketing Surveillance Study of Atrovent® in Chronic Obstructive Airways Disease
- First Posted Date
- 2014-09-11
- Last Posted Date
- 2014-09-11
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 1039
- Registration Number
- NCT02236715
Trial to Determine the Comparability of Ipratropium Bromide Hydrofluoroalkane (HFA)-134a Inhalation Aerosol to ATROVENT® Chlorofluorocarbon (CFC) Inhalation Aerosol, in Patients With Chronic Obstructive Pulmonary Disease (COPD)
Phase 2
Completed
- Conditions
- Pulmonary Disease, Chronic Obstructive
- Interventions
- First Posted Date
- 2014-09-10
- Last Posted Date
- 2014-09-10
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 30
- Registration Number
- NCT02236169
A Study of Pre-hospital Treatment of Acute Myocardial Infarction Based on Diagnosis by Interpretation of Remotely Acquired ECG and Thrombolysis With Accelerated Alteplase ( Actilyse®)
Terminated
- Conditions
- Myocardial Infarction
- Interventions
- Drug: Standard therapy
- First Posted Date
- 2014-09-10
- Last Posted Date
- 2014-09-10
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 59
- Registration Number
- NCT02235389
Study to Assess the Efficacy of Ipratropium Bromide Associated With High Dose Salbutamol by Repeated Nebulisation Versus Repeat Nebulisation of Salbutamol Alone, in Acute Asthmatic Attacks in Young Children
Phase 4
Terminated
- Conditions
- Asthma
- Interventions
- First Posted Date
- 2014-09-10
- Last Posted Date
- 2014-09-10
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 3
- Registration Number
- NCT02235428
Study to Assess the Safety of Ipratropium Bromide, in Patients With Chronic Obstructive Pulmonary Disease (COPD)
Phase 2
Completed
- Conditions
- Pulmonary Disease, Chronic Obstructive
- Interventions
- First Posted Date
- 2014-09-10
- Last Posted Date
- 2014-09-12
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 57
- Registration Number
- NCT02236182
A Randomised, Parallel-group, Double-blind, Double-dummy Study to Compare the Effects of Lacidipine Versus Bendrofluazide on Markers of Platelet Activation and Haemorheological Factors in Hypertensive Patients
Phase 4
Completed
- Conditions
- Hypertension
- Interventions
- First Posted Date
- 2014-09-10
- Last Posted Date
- 2014-09-10
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 26
- Registration Number
- NCT02235402